- Why Axiom hopes it’s ‘solved 2 major potholes’ that have hurt other stem cell biotechsWhen Axiom's stem cell therapy demonstrated a 0% mortality rate over two years in potentially fatal newborn neurological diseases this week, the biotech's leadership saw a broader validation for th…Fierce Biotech · 11d ago↗ source
- STAT+: Medicare Advantage insurers face new bipartisan scrutiny over AI and care denialsBlumenthal, Hawley press UnitedHealth, Humana, CVS for documents related to using AI to deny or delay care.STAT · 12d ago↗ source
- STAT+: Under a new leader, the FDA’s biologics center moves to steady itself after stormy chapterAfter his predecessor's turbulent tenure, Karim Mikhail is working to restore staff morale and revisit controversial rejections.